Combination therapy trial for locally advanced, metastatic HCC underway

CStone Pharmaceuticals and Blueprint Medicines Corporation announced the first patient dosed in a phase 1b/2 trial of fisobatinib in combination with CS1001 for the treatment of locally advanced or metastatic hepatocellular carcinoma, according to a press release.Investigators will assess the potential for two complementary treatment approaches including precision therapy and immune-oncology therapy to enhance anti-tumor activity at multiple clinical sites in China.“HCC is a particularly aggressive disease and China is currently faced with enormous challenges due to limited effectiveRead More

Share on facebook
Share on twitter
Share on linkedin